EarningsAnalyst notes reported results that exceeded expectations, reinforcing the group's growth and margin expansion narrative.
LeadershipAppointment of Alireza Tajbakhsh as CEO, along with his international leadership experience, suggests strategic continuity and supports expansion ambitions.
Segment GrowthAnalyst highlights broad-based organic growth across Specialty Pharma, Veterinary Services and improved US orthopaedics as a driver of revenue momentum.